A Novel Neuropeptide Platform with Promising Therapeutic Applications
We have created a portfolio of novel neuropeptides that are in various stages of development and pre-clinical evaluation for the treatment of stress-related disorders. The lead product candidate, PT00114, is targeted to treat PTSD and Drug & Alcohol Addiction without interfering with normal brain function.
Over 15 years of accumulated research, Protagenic Therapeutics’ scientists are discovering the actions of a family of neuropeptides called TCAPs, from the genetic level through systemic biological changes that impact physiology and behavior.
The potential to improve mental health by counterbalancing stress overdrive and restoring the health of neuronal cells represents an exciting paradigm shift in treatment approaches.
Leveraging activity impacting multiple neuropathological processes, Protagenic is reaching beyond the boundaries of traditional therapeutics for stress-related disorders, by focusing on restoring the body’s natural equilibrium.
An immortalized N38 neuron with the expression of immunoreactive TCAP shown in green fluorescence. This image suggests the role of TCAP in neuronal process development. It shows that the expression of the immunoreactive TCAP occurs around the neuronal periphery — consistent with endoplasmic reticulum and golgi expression, but more importantly associated in regions of neurite growth. This led to understanding the mechanism by which TCAP is thought to regulate inter-neuronal interaction.
Source: Prof. Denise Belsham and Arij Al Chawaf, Ph.D, Department of Physiology, the University of Toronto.
Our technology in numbers
41
Amino acids in length
400
Million years of molecular conservation
8
Major human disease targets
14
Years of Development at Protagenic Therapeutics, Inc.